The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-04 and is reviewed periodically as new material appears.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
In 1949, in the Superga air disaster, a plane carrying almost the whole team crashed into the Basilica of Superga in the Turin hills. Torino currently plays its home games at the Stadio Olimpico "Grande Torino", named after the team of the 1940s, which was a host stadium for the 1934 FIFA World Cup and the venue of the opening ceremonies of the XX Winter Olympics and IX Paralympic Winter Games and the closing ceremony of the former; moreover the team recently rebuilt the historic Stadio Filadelfia, used for games of the youth teams and trainings of the first squad, and the planned seat of the team museum. The city hosted the final stages of the EuroBasket 1979. The most important basketball club team is the Auxilium Torino, refounded in 2009, playing in the Italian LBA. In 2018 Auxilium Torino went to win its first Italian Basketball Cup ever. Turin hosted the 2006 Winter Olympics in February 2006. Turin is the largest city to have ever hosted a Winter Olympics, and was the largest metropolitan area to host them at the time. The city was awarded with the title of European Capital of Sport 2015. The candidature sees the city strongly committed to increasing sports activities. The city hosted the ATP Finals tennis event from 2021 to 2025. Turin hosted the 2025 Special Olympics World Winter Games.
β-Hydroxy β-methylglutaryl-CoA (HMG-CoA), also known as 3-hydroxy-3-methylglutaryl coenzyme A, is an intermediate in the mevalonate and ketogenesis pathways. It is formed from acetyl CoA and acetoacetyl CoA by HMG-CoA synthase. The research of Minor J. Coon and Bimal Kumar Bachhawat in the 1950s at University of Illinois led to its discovery. HMG-CoA is a metabolic intermediate in the metabolism of the branched-chain amino acids, which include leucine, isoleucine, and valine. Its immediate precursors are β-methylglutaconyl-CoA (MG-CoA) and β-hydroxy β-methylbutyryl-CoA (HMB-CoA). HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, a necessary step in the biosynthesis of cholesterol.
== External links == Procter and Gamble web page for Intrinsa. Information on Intrinsa and User Forum Patch 'to boost female sex drive' FDA Looks at P&G's Sex-Drive Drug Women's sexual health deserves equal attention
=== United States === Radiology is a field in medicine that has expanded rapidly after 2000 due to advances in computer technology, which is closely linked to modern imaging techniques. Applying for residency positions in radiology has become highly competitive. Applicants are often near the top of their medical school classes, with high USMLE (board) examination scores. Diagnostic radiologists must complete prerequisite undergraduate education, four years of medical school to earn a medical degree (D.O. or M.D.), one year of internship, and four years of residency training. After residency, most radiologists pursue one or two years of additional specialty fellowship training. The American Board of Radiology (ABR) administers professional certification in Diagnostic Radiology, Radiation Oncology, and Medical Physics as well as subspecialty certification in neuroradiology, nuclear radiology, pediatric radiology, and vascular and interventional radiology. "Board Certification" in diagnostic radiology requires successful completion of two examinations. The Core Exam is given after 36 months of residency. Although previously taken in Chicago or Tucson, Arizona, beginning in February 2021, the computer test transitioned permanently to a remote format. It encompasses 18 categories. A passing score is 350 or above. A fail on one to five categories was previously a Conditioned exam; beginning in June 2021, the conditioned category will no longer exist, and the test will be graded as a whole. The Certification Exam can be taken 15 months after completion of the Radiology residency.
By 25 September, an army of around 40,000 Iraqi, Syrian, and Houthi militants were concentrated around the Golan Heights, which the Institute for the Study of War argued was to defend against an Israeli invasion of Lebanon. The number of displaced Lebanese people reached an estimated 500,000. On 26 September, an Israeli strike on a three-story building in Younine killed at least 19 Syrians and a Lebanese person, mostly women or children, and injured eight others. On 27 September, Israel struck Hezbollah's central headquarters in Beirut, targeting Hezbollah leader Hassan Nasrallah. Al-Manar reported that four buildings collapsed in the attack. At least five other people died, including Ali Karaki, Hezbollah's commander of the southern front since 1982, and at least 100 were injured. On 28 September, the Lebanese National News Agency reported that IDF strikes struck civil defense centres and a medical clinic in Taybeh and Deir Siriane killing 11 medical staff and injuring 10 others. On 29 September, an Israeli air strike on a home in Dahr-al-Ain killed at least 11 people. The Lebanese National News Agency reported that at least 17 members of a family were killed and several others were trapped under rubble in an Israeli air strike in Zboud. An Israeli strike in Ain El Delb killed 45 people and injured at least 75 others. An Israeli strike in Bekaa killed 12 people and injured 20 others. On 30 September, Israel informed the United States that it intended to carry out a ground maneuver in Lebanon aimed at clearing Hezbollah's infrastructure along the border.
Sources: en.wikipedia.org
The three substrates of this enzyme are leucocyanidin, reduced nicotinamide adenine dinucleotide phosphate (NADPH), and a proton. Its products are catechin, oxidised NADP+, and water. This enzyme is an oxidoreductase, with the systematic name (2R,3S)-catechin:NADP+ 4-oxidoreductase. It is also called leucocyanidin reductase.
== Predicted properties == Very few properties of flerovium or its compounds have been measured; due to its extremely limited and expensive production and the fact that it decays very quickly. A few singular properties have been measured, but for the most part, properties of flerovium remain unknown and only predictions are available.
== Antiviral activity == Phenformin is a drug that blocks a key energy-producing enzyme in cells (NADH:ubiquinone oxidoreductase). It has shown promising activity as a broad-spectrum antiviral. Using a computational approach that analyzed how viruses change cell metabolism, researchers found that infections including SARS-CoV-2, influenza A, and dengue virus all rely on similar metabolic pathways. By targeting these pathways, phenformin could reduce SARS-CoV-2 and dengue virus replication in lab experiments and even showed antiviral effects against SARS-CoV-2 in a Syrian hamster model. These findings suggest phenformin could be developed as a therapy that fights multiple viruses by disrupting the resources they need to replicate.
This scenario usually occurs at very low solidification velocities (< 1 μm s−1) or with extremely fine particles because they can move by Brownian motion away from the front. The resultant structure contains no macroporosity. If one were to increase the solidification speed, the size of the particles or solid loading moderately, the particles begin to interact in a meaningful way with the approaching ice front. The result is typically a lamellar or cellular templated structure whose exact morphology depends on the particular conditions of the system. It is this type of solidification that is targeted for porous materials made by freeze-casting. The third possibility for a freeze-cast structure occurs when particles are given insufficient time to segregate from the suspension, resulting in complete encapsulation of the particles within the ice front. This occurs when the freezing rates are rapid, particle size becomes sufficiently large, or when the solids loading is high enough to hinder particle motion. To ensure templating, the particles must be ejected from the oncoming front. Energetically speaking, this will occur if there is an overall increase in free energy if the particle were to be engulfed (Δσ > 0).
Sources: en.wikipedia.org
Sequence variation of Bemisia tabaci Chemosensory protein 2 in cryptic species B and Q: new DNA markers for whitefly recognition. Gene 2016a; 576: 284-291. 26. Zhu J, Wang G, Pelosi P. Plant transcriptomes reveal hidden guests. Biochem Biophys Res Commun. 2016; 474: 497-502. 27. Perkin LC, Friesen KS, Flinn PW, Oppert B. Venom gland components of the ectoparasitoid wasp, Anisopteromalus calandrae. J. Venom Res. 2015; 6: 19-37. 28. Celorio-Mancera MdP, Sundmalm SM, Vogel H, Rutishauser D, Ytterberg AJ, Zubarv RA et al. Chemosensory proteins, major salivary factors in caterpillar mandibular glands. Insect Biochem Mol Biol. 2012; 42: 796-805. 29. González-Caballero N, Valenzuela JG, Ribeiro JMC, Cuervo P, Brazil RP. Transcriptome exploration of the sex pheromone gland of Lutzomyia longipalpis (Diptera: Psychodidae: Phlebotominae). Parasit Vect. 2013; 6: 56. 30. Liu YL, Guo H, Huang LQ, Pelosi P, Wang CZ. Unique function of a chemosensory protein in the proboscis of two Helicoverpa species. J Exp Biol. 2014; 217: 1821-1826. 31. Zhu J, Iovinella I, Dani FR, Liu YL, Huang LQ, Liu Y, et al. Conserved chemosensory proteins in the proboscis and eyes of Lepidoptera. Int J Biol Sci. 2016; 12: 1394-1404. 32. Xuan N, Guo X, Xie HY, Lou QN, Bo LX, Liu GX, et al. Increased expression of CSP and CYP genes in adult silkworm females exposed to avermectins. Insect Sci. 2015; 22: 203-219. 33. Sabatier L, Jouanguy E, Dostert C, Zachary D, Dimarcq JL, Bulet P, et al.
== Treatments == Because different types of myopathies are caused by many different pathways, there is no single treatment for myopathy. Treatments range from treatment of the symptoms to very specific cause-targeting treatments. Drug therapy, physical therapy, bracing for support, surgery, and massage are all current treatments for a variety of myopathies.
== Environmental record == According to the 2022 "Top 100 Polluters Indexes" published by the University of Massachusetts, Amherst's "Political Economy Research Institute" (PERI), BASF was ranked the #2 largest polluter of air and #14 largest polluter of water in 2020, the most recent year for which data is available from the U.S. Environmental Protection Agency. In 2006, BASF was included in the Climate Leadership Index for their efforts in relation to climate change and greenhouse gas emissions. The BASF Company and Columbia University formed a partnership to further research "environmentally benign and sustainable energy sources". The company has recently reported their emissions in 2006 to be "1.50 million metric tons of waste," which is a decrease from previous years. The amount of waste BASF produces has continued to fall. While BASF publishes its environmental information in the US and Europe, Greenpeace has expressed deep concerns at BASF's refusal to release environmental information on its operations in China. In May 2009, a BASF Plant in Hannibal, Missouri, United States, accidentally discharged chromium into the Mississippi River. The local Department of Natural Resources performed tests in December 2009 showing the chromium levels did not exceed regulatory safety limits. BASF worked with the Missouri Department of Natural Resources (MoDNR) to resolve questions regarding the elevated level of hexavalent chromium that was detected in the effluent from one of its permitted outfalls into the Mississippi River.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.